Literature DB >> 17288638

The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study.

Louisa Degenhardt1, Chris Tennant, Stuart Gilmour, David Schofield, Louise Nash, Wayne Hall, Diana McKay.   

Abstract

BACKGROUND: The aim was to examine the temporal relationships over 10 months between cannabis use and symptoms of psychosis and depression in people with schizophrenia and related disorders. The design was a prospective study of 101 patients with schizophrenia and related disorders who were assessed monthly over 10 months on medication compliance, cannabis and other drug use, symptoms of depression and symptoms of psychosis.
METHOD: Linear regression methods to assess relationships between cannabis use and symptoms of psychosis and depression while adjusting for serial dependence, medication compliance and other demographic and clinical variables.
RESULTS: Cannabis use predicted a small but statistically significant increase in symptoms of psychosis, but not depression, after controlling for other differences between cannabis users and non-users. Symptoms of depression and psychosis did not predict cannabis use.
CONCLUSION: Continued cannabis use by persons with schizophrenia predicts a small increase in psychotic symptom severity but not vice versa.

Entities:  

Mesh:

Year:  2007        PMID: 17288638     DOI: 10.1017/S0033291707009956

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  27 in total

1.  A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.

Authors:  Daniel Wagner; Philip Koester; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Martin Hellmich; Joerg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2014-08-27       Impact factor: 4.530

2.  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Authors:  Daniel J Foti; Roman Kotov; Lin T Guey; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

3.  Psychoses, PTSD, and depression in Somali refugees in Minnesota.

Authors:  Jerome Kroll; Ahmed Ismail Yusuf; Koji Fujiwara
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-03-31       Impact factor: 4.328

4.  THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia.

Authors:  David D Aguilar; Andrea Giuffrida; Daniel J Lodge
Journal:  J Psychopharmacol       Date:  2015-10-28       Impact factor: 4.153

5.  Cannabis use disorders in schizophrenia: effects on cognition and symptoms.

Authors:  Pamela DeRosse; Alyson Kaplan; Katherine E Burdick; Todd Lencz; Anil K Malhotra
Journal:  Schizophr Res       Date:  2010-05-18       Impact factor: 4.939

6.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

7.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

9.  Should burden of disease estimates include cannabis use as a risk factor for psychosis?

Authors:  Louisa Degenhardt; Wayne D Hall; Michael Lynskey; John McGrath; Jennifer McLaren; Bianca Calabria; Harvey Whiteford; Theo Vos
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

10.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.